CA2408008A1 - Pharmaceutical compositions containing a glycopeptide antibiotic and a cyclodextrin - Google Patents

Pharmaceutical compositions containing a glycopeptide antibiotic and a cyclodextrin Download PDF

Info

Publication number
CA2408008A1
CA2408008A1 CA002408008A CA2408008A CA2408008A1 CA 2408008 A1 CA2408008 A1 CA 2408008A1 CA 002408008 A CA002408008 A CA 002408008A CA 2408008 A CA2408008 A CA 2408008A CA 2408008 A1 CA2408008 A1 CA 2408008A1
Authority
CA
Canada
Prior art keywords
substituted
alkynyl
alkyl
alkenyl
cycloalkenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002408008A
Other languages
French (fr)
Other versions
CA2408008C (en
Inventor
J. Kevin Judice
Jeng-Pyng Shaw
Yongqi Mu
Michael W. Conner
John Pace
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cumberland Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CA2726789A priority Critical patent/CA2726789A1/en
Publication of CA2408008A1 publication Critical patent/CA2408008A1/en
Application granted granted Critical
Publication of CA2408008C publication Critical patent/CA2408008C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
    • C07K9/006—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure
    • C07K9/008—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence being part of a ring structure directly attached to a hetero atom of the saccharide radical, e.g. actaplanin, avoparcin, ristomycin, vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nanotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Disclosed are pharmaceutical compositions containing a cyclodextrin and a therapeutically effective amount of a glycopeptide antibiotic or a salt thereof. Also disclosed are methods of treating a bacterial disease in a mammal by administering such pharmaceutical compositions.

Claims (19)

1. A composition comprising a cyclodextrin and a glycopeptide antibiotic, or a pharmaceutically acceptable salt thereof.
2. The composition of claim 1 which further comprises water.
3. The composition of claim 1 which is a powder.
4. The composition of claim 1 which is a lyophilized powder.
5. A pharmaceutical composition comprising an aqueous cyclodextrin carrier and a therapeutically effective amount of a glycopeptide antibiotic, or a pharmaceutically acceptable salt thereof.
6. The pharmaceutical composition of Claim 5, wherein the pharmaceutical composition comprises:
(a) a therapeutically effective amount of a glycopeptide antibiotic, or a pharmaceutically acceptable salt thereof;
(b) 1 to 40 weight percent of a cyclodextrin; and (c) 60 to 99 weight percent of water, provided that the components of the composition total 100 weight percent.
7. The pharmaceutical composition of Claim 5, wherein the cyclodextrin is hydroxypropyl-.beta.-cyclodextrin or sulfobutyl ether .beta.-cyclodextrin.
8. The pharmaceutical composition of Claim 7, wherein the cyclodextrin is hydroxypropyl-.beta.-cyclodextrin.
9. The pharmaceutical composition of Claim 6, wherein the cyclodextrin comprises about 5 to 35 weight percent of the composition.
10. The pharmaceutical composition of Claim 9, wherein the cyclodextrin comprises about 10 to 30 weight percent of the composition.
11. The pharmaceutical composition of Claim 6, wherein the glycopeptide antibiotic is a lipidated glycopeptide antibiotic.
12. The pharmaceutical composition of Claim 1, wherein the glycopeptide antibiotic is a compound of formula I:

wherein:
R1 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl, heterocyclic and -R a-Y-R b-(Z)x; or R1 is a saccharide group optionally substituted with -R a-Y-R b-(Z)x, R f -C(O)R f, or -C(O)-R a-Y-R b-(Z)x;
R2 is hydrogen or a saccharide group optionally substituted with -R a-Y-R b-(Z)x, R f, -C(O)R f, or -C(O)-R a-Y-R b-(Z)x;
R3 is -OR c, -NR c R c, -O-R a-Y-R b-(Z)x, -NR c-R a-Y-R b-(Z)x, -NR c R e;
or -O-R e; or R3 is a nitrogen-linked, oxygen-linked, or sulfur-linked substituent that comprises one or more phosphono groups;
R4 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, -R a-Y-R b-(Z)x, -C(O)R d and a saccharide group optionally substituted with -R a-Y-R b-(Z)x, R
f, -C(O)R f, or -C(O)-R a-Y-R b-(Z)x;
R5 is selected from the group consisting of hydrogen, halo, -CH(R c)-NR c R c, -CH(R c)-NR c R c, -CH(R c)-NR c-R a-Y-R b-(Z)x,-CH(R c)-R
x, -CH(R c)-NR c-R a-C(=O)-R x, and a substituent that comprises one or more phosphono groups;
R6 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, -R a-Y-R b-(Z)x, -C(O)R d and a saccharide group optionally substituted with -NR c-R a-Y-R b-(Z)x, or R5 and R6 can be joined, together with the atoms to which they are attached, form a heterocyclic ring optionally substituted with -NR c-R a-Y-R b-(Z)x;
R7 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl,-R a-Y-R b-(Z)x, and -C(O)R d;
R8 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl and heterocyclic;
R9 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, allcenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl and heterocyclic;
R10 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl and heterocyclic; or R8 and R10 are joined to form -Ar1-O-Ar2-, where Ar1 and Ar2 are independently arylene or heteroarylene;

R11 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl and heterocyclic, or R10 and R11 are joined, together with the carbon and nitrogen atoms to which they are attached, to form a heterocyclic ring;

R12 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl, heterocyclic, -C(O)R d, -C(NH)R d, -C(O)NR c R c, -C(O)OR d, -C(NH)NR c R c and -R a-Y-R b-(Z) x, or R11 and R12 are joined, together with the nitrogen atom to which they are attached, to form a heterocyclic ring;

R13 is selected from the group consisting of hydrogen or -OR14;

R14 is selected from hydrogen, -C(O)R d and a saccharide group;

each R a is independently selected from the group consisting of alkylene, substituted alkylene, alkenylene, substituted alkenylene, alkynylene and substituted alkynylene;

each R b is independently selected from the group consisting of a covalent bond, alkylene, substituted alkylene, alkenylene, substituted alkenylene, alkynylene and substituted alkynylene, provided R b is not a covalent bond when Z is hydrogen;

each R c is independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl, heterocyclic and -C(O)R d;

each R d is independently selected from the group consisting of alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl and heterocyclic;

R e is a saccharide group;

each R f is independently alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl, or heterocyclic;

R x is an N-linked amino saccharide or an N-linked heterocycle;

X1, X2 and X3 are independently selected from hydrogen or chloro;

each Y is independently selected from the group consisting of oxygen, sulfur, -S-S-, -NR c-, -S(O)-, -SO2-, -NR c C(O)-, -OSO2-, -OC(O)-, -NR c SO2-, -C(O)NR c-, -C(O)O-, -SO2NR c-, -SO2O-, -P(O)(OR c)O-, -P(O)(OR c)NR c-, -OP(O)(OR c)O-,-OP(O)(OR c)NR c-, -OC(O)O-, -NR c C(O)O-, -NR c C(O)NR c-, -OC(O)NR c-, -C(=O)-, and -NR cSO2NR c-;

each Z is independently selected from hydrogen, aryl, cycloalkyl, cycloalkenyl, heteroaryl and heterocyclic;

n is 0, I or 2; and x is 1 or 2;

or a pharmaceutically acceptable salt, stereoisomer, or prodrug thereof.
13. The pharmaceutical composition of Claim 1, wherein the glycopeptide antibiotic has formula II:

wherein:

R19 is hydrogen;

R20 is -R a-Y-R b-(Z) x, R f, -C(O)R f, or -C(O)-R a-Y-R b-(Z) x; and R a, Y, R b, Z, x, R f, R3, and R5 are as defined in Claim 7;

or a pharmaceutically acceptable salt, stereoisomer, or prodrug thereof.
14. A method of treating a mammal having a bacterial disease, the method comprising administering to the mammal a pharmaceutical composition of any one of Claims 1-13.
15. A method of treating a bacterial disease in a mammal, the method comprising administering to the mammal a therapeutically effective amount of a glycopeptide antibiotic in combination with a cyclodextrin.
16. A method for reducing tissue accumulation of a glycopeptide antibiotic when administered to a mammal, the method comprising administering the glycopeptide antibiotic to the mammal in a pharmaceutical composition comprising a cyclodextrin and a therapeutically effective amount of the glycopeptide antibiotic or a pharmaceutically acceptable salt thereof.
17. A method for reducing nephrotoxicity produced by a glycopeptide antibiotic when administered to a mammal, the method comprising administering the glycopeptide antibiotic to the mammal in a pharmaceutical composition comprising a cyclodextrin and a therapeutically effective amount of the glycopeptide antibiotic or a pharmaceutically acceptable salt thereof.
18. A method for reducing histamine release produced by a glycopeptide antibiotic when administered to a mammal, the method comprising administering the glycopeptide antibiotic to the mammal in a pharmaceutical composition comprising a cyclodextrin and a therapeutically effective amount of the glycopeptide antibiotic or a pharmaceutically acceptable salt thereof.
19. A method for reducing vascular irritation produced by a glycopeptide antibiotic when administered to a mammal, the method comprising administering the glycopeptide antibiotic to the mammal in a pharmaceutical composition comprising a cyclodextrin and a therapeutically effective amount of the glycopeptide antibiotic or a pharmaceutically acceptable salt thereof.
CA2408008A 2000-02-05 2001-05-01 Pharmaceutical compositions containing a glycopeptide antibiotic and a cyclodextrin Expired - Lifetime CA2408008C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2726789A CA2726789A1 (en) 2000-02-05 2001-05-01 Cyclodextrin containing glycopeptide antibiotic compositions

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US20117800P 2000-05-02 2000-05-02
US60/201,178 2000-05-02
US21341500P 2000-06-22 2000-06-22
US21341000P 2000-06-22 2000-06-22
US21341700P 2000-06-22 2000-06-22
US21314600P 2000-06-22 2000-06-22
US21342800P 2000-06-22 2000-06-22
US60/213,417 2000-06-22
US60/213,410 2000-06-22
US60/213,146 2000-06-22
US60/213,415 2000-06-22
US60/213,428 2000-06-22
US22672700P 2000-08-18 2000-08-18
US60/226,727 2000-08-18
PCT/US2001/014000 WO2001082971A2 (en) 2000-05-02 2001-05-01 Cyclodextrin containing glycopeptide antibiotic compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA2726789A Division CA2726789A1 (en) 2000-02-05 2001-05-01 Cyclodextrin containing glycopeptide antibiotic compositions

Publications (2)

Publication Number Publication Date
CA2408008A1 true CA2408008A1 (en) 2001-11-08
CA2408008C CA2408008C (en) 2011-01-18

Family

ID=27569291

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2408008A Expired - Lifetime CA2408008C (en) 2000-02-05 2001-05-01 Pharmaceutical compositions containing a glycopeptide antibiotic and a cyclodextrin
CA2726789A Abandoned CA2726789A1 (en) 2000-02-05 2001-05-01 Cyclodextrin containing glycopeptide antibiotic compositions

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2726789A Abandoned CA2726789A1 (en) 2000-02-05 2001-05-01 Cyclodextrin containing glycopeptide antibiotic compositions

Country Status (12)

Country Link
US (5) US6858584B2 (en)
EP (1) EP1278549B1 (en)
JP (2) JP4870314B2 (en)
CN (1) CN1223378C (en)
AT (1) ATE416791T1 (en)
AU (1) AU2001259306A1 (en)
BR (1) BR0110530A (en)
CA (2) CA2408008C (en)
DE (1) DE60136926D1 (en)
ES (1) ES2316445T3 (en)
SI (1) SI1278549T1 (en)
WO (1) WO2001082971A2 (en)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001082971A2 (en) 2000-05-02 2001-11-08 Theravance, Inc. Cyclodextrin containing glycopeptide antibiotic compositions
UA75083C2 (en) 2000-06-22 2006-03-15 Тераванс, Інк. Derivatives of glycopeptidephosphonates
TWI312785B (en) 2001-08-24 2009-08-01 Theravance Inc Process for preparing vancomycin derivatives
TWI275594B (en) 2001-08-24 2007-03-11 Theravance Inc Process for preparing vancomycin phosphonate derivatives
US7499410B2 (en) * 2001-12-26 2009-03-03 Cisco Technology, Inc. Fibre channel switch that enables end devices in different fabrics to communicate with one another while retaining their unique fibre channel domain—IDs
US7599360B2 (en) * 2001-12-26 2009-10-06 Cisco Technology, Inc. Methods and apparatus for encapsulating a frame for transmission in a storage area network
GB0206930D0 (en) * 2002-03-23 2002-05-08 Univ Durham Method and apparatus for the formation of hydrophobic surfaces
US7406034B1 (en) 2002-04-01 2008-07-29 Cisco Technology, Inc. Methods and apparatus for fibre channel frame delivery
US7616637B1 (en) 2002-04-01 2009-11-10 Cisco Technology, Inc. Label switching in fibre channel networks
US7206288B2 (en) * 2002-06-12 2007-04-17 Cisco Technology, Inc. Methods and apparatus for characterizing a route in fibre channel fabric
US7433326B2 (en) 2002-11-27 2008-10-07 Cisco Technology, Inc. Methods and devices for exchanging peer parameters between network devices
JP2006528704A (en) * 2003-05-27 2006-12-21 セラヴァンス インコーポレーテッド Use of polyene macrolide antifungal agents in combination with glycopeptide antibacterial agents
TWI342312B (en) * 2003-10-22 2011-05-21 Theravance Inc Hydrochloride salts of a glycopeptide phosphonate derivative
JP2008512490A (en) * 2004-09-08 2008-04-24 チェルシー・セラピューティクス，インコーポレイテッド Metabolically inactive folate antagonists for treating abnormal cell proliferation and inflammation disorders
US7593324B2 (en) * 2004-10-25 2009-09-22 Cisco Technology, Inc. Graceful port shutdown protocol for fibre channel interfaces
US7916628B2 (en) * 2004-11-01 2011-03-29 Cisco Technology, Inc. Trunking for fabric ports in fibre channel switches and attached devices
EP2314599A1 (en) 2004-11-29 2011-04-27 National University Corporation Nagoya University Glycopeptide antibiotic monomer derivatives
US7649844B2 (en) * 2004-12-29 2010-01-19 Cisco Technology, Inc. In-order fibre channel packet delivery
US20100204178A1 (en) 2006-10-02 2010-08-12 James Cloyd Novel parenteral carbamazepine formulation
US7795207B2 (en) 2005-11-21 2010-09-14 Harald Labischinski Lipopeptide compositions
DE102005056194A1 (en) * 2005-11-21 2007-07-12 Combinature Biopharm Ag New lipopeptide compositions
NZ568288A (en) * 2005-11-28 2012-02-24 Verrow Pharmaceuticals Inc Compositions comprising a a cyclodextrin and a nephrotoxic anticancer drug
US7658913B2 (en) 2005-11-28 2010-02-09 Verrow Pharmaceuticals, Inc. Compositions useful for reducing nephrotoxicity and methods of use thereof
MX2010010998A (en) * 2008-04-07 2011-01-25 Chelsea Therapeutics Inc Antifolate compositions.
EP2324041A4 (en) 2008-08-13 2012-06-13 Targanta Therapeutics Corp Phosphonated rifamycins and uses thereof for the prevention and treatment of bone and joint infections
DK2337575T3 (en) 2008-08-30 2016-05-23 Medicines Co A method of treatment with single doses of oritavancin
JP2012525391A (en) 2009-04-28 2012-10-22 ターガンタ セラピューティクス コーポレイション Treatment method of bacterial infection using oritavancin
US20110124650A1 (en) * 2009-07-08 2011-05-26 Chelsea Therapeutics, Inc. Stable crystalline salts of antifolate compounds
EP2496237A2 (en) * 2009-11-06 2012-09-12 Chelsea Therapeutics, Inc. Enzyme inhibiting compounds
US20110237609A1 (en) * 2010-03-29 2011-09-29 Chelsea Therapeutics, Inc. Antifolate compositions
WO2012078708A1 (en) 2010-12-07 2012-06-14 Chelsea Therapeutics, Inc. Combination comprising methotrexate and an antifolate compound
ES2949169T3 (en) 2013-08-26 2023-09-26 Melinta Therapeutics Inc Procedures to treat bacteremia and osteomyelitis using oritavancin
US9697843B2 (en) 2014-04-30 2017-07-04 Qualcomm Incorporated High band excitation signal generation
AU2017221435A1 (en) * 2016-02-18 2018-09-06 Melinta Therapeutics, Inc. Oritavancin formulations
WO2017179003A1 (en) 2016-04-15 2017-10-19 Lupin Limited Topical compositions for ophthalmic and otic use
CN107325159A (en) * 2016-04-29 2017-11-07 中国科学院上海药物研究所 One class vancomycin derivatives, its preparation method, pharmaceutical composition and purposes
EA201892413A1 (en) 2016-05-09 2019-05-31 Кселлия Фармасьютикалз Апс STABILIZED GLYOPEPTID ANTIBIOTIC PREPARATIONS
CN110198959B (en) 2017-01-03 2023-03-28 北卡罗米纳大学查佩尔希尔分校 Nitric oxide releasing alginate as biodegradable antimicrobial scaffolds and related methods
CA3055474A1 (en) 2017-03-28 2018-10-04 The University Of North Carolina At Chapel Hill Nitric oxide-releasing polyaminoglycosides as biodegradable antibacterial scaffolds and methods pertaining thereto
CN111511350B (en) 2017-07-07 2023-10-13 埃皮辛特瑞柯斯公司 Compositions for parenteral administration of therapeutic agents
CN107987131B (en) * 2017-11-16 2021-03-09 上海来益生物药物研究开发中心有限责任公司 Compound with anti-drug-resistance bacterial activity, preparation method and application thereof
EP3762039A4 (en) 2018-03-06 2021-12-22 The University of North Carolina at Chapel Hill Nitric oxide-releasing cyclodextrins as biodegradable antibacterial scaffolds and methods pertaining thereto
EA202092635A1 (en) 2018-06-13 2021-03-23 Дибли Аг PREPARATION OF CONDENSED TRIAZEPINE DERIVATIVES AND THEIR USE AS BET INHIBITORS
CN113383019B (en) 2018-12-28 2023-11-17 北卡罗来纳大学教堂山分校 Nitric oxide releasing antimicrobial polymers and scaffolds made therefrom and methods relating thereto
US20220133844A1 (en) 2020-10-30 2022-05-05 Somerset Therapeutics, Llc Glycopeptide antibiotics liquid formulations and methods and uses thereof
EP4014965A1 (en) 2020-12-16 2022-06-22 EVER Valinject GmbH Aqueous solution
EP4014969A1 (en) 2020-12-16 2022-06-22 EVER Valinject GmbH Aqueous solution

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US207797A (en) * 1878-09-10 Improvement in check-rein hooks
US229775A (en) * 1880-07-06 Eobeet h
US87494A (en) * 1869-03-02 William h
US73371A (en) * 1868-01-14 Robert moxley
US77280A (en) * 1868-04-28 John l
US63916A (en) * 1867-04-16 Improvement in cotton peess
US4371673A (en) 1980-07-21 1983-02-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Water soluble forms of retinoids
DE3372705D1 (en) 1982-04-30 1987-09-03 Takeda Chemical Industries Ltd Pharmaceutical composition and its use
DE3346123A1 (en) 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse PHARMACEUTICAL PREPARATIONS OF SUBSTANCES MEDICAL OR UNSTABLE IN WATER AND METHOD FOR THE PRODUCTION THEREOF
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US4698327A (en) * 1985-04-25 1987-10-06 Eli Lilly And Company Novel glycopeptide derivatives
US4643987A (en) * 1985-08-14 1987-02-17 Eli Lilly And Company Modified glycopeptides
US4639433A (en) * 1985-08-14 1987-01-27 Eli Lilly And Company Glycopeptide derivatives
US5002935A (en) 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
EP0335545B2 (en) 1988-03-29 1998-09-23 University Of Florida Pharmaceutical formulations for parenteral use
US5411947A (en) 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
US5196404B1 (en) 1989-08-18 1996-09-10 Biogen Inc Inhibitors of thrombin
ZA909847B (en) * 1989-12-13 1992-08-26 Lilly Co Eli Glycopeptide derivatives
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (en) * 1990-01-23 1999-01-15 . Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9012663D0 (en) * 1990-06-07 1990-08-01 Erba Carlo Spa Galenic formulations containing cyclodextrins
WO1991019734A2 (en) 1990-06-15 1991-12-26 Majesty (Her) In Right Of Canada As Represented By The National Research Council Of Canada Thrombin inhibitors based on the amino acid sequence of hirudin
US5750509A (en) * 1991-07-29 1998-05-12 Gruppo Lepetit S.P.A. Amide derivatives of antibiotic A 40926
WO1993007904A1 (en) * 1991-10-16 1993-04-29 Schering Corporation Lipophilic oligosaccharide antibiotic salt compositions
IT1251751B (en) * 1991-10-31 1995-05-23 Sclavo Ricerca S R L METHOD FOR THE CULTURE OF MICROORGANISMS OF THE HELICOBACTER, CAMPYLOBACTER AND ARCOBACTER GENERATIONS, USING CULTURE SOILS CONTAINING CYCLODESTRINE OR METHYL-CELLULOSE OR THEIR MIXTURES
US5602112A (en) 1992-06-19 1997-02-11 Supergen, Inc. Pharmaceutical formulation
US5324718A (en) * 1992-07-14 1994-06-28 Thorsteinn Loftsson Cyclodextrin/drug complexation
US5472954A (en) * 1992-07-14 1995-12-05 Cyclops H.F. Cyclodextrin complexation
JPH08503951A (en) * 1992-12-02 1996-04-30 インサイト・ビジョン・インコーポレイテッド Drug delivery system using cyclodextrin and polymer
CA2134753A1 (en) 1993-03-08 1994-09-15 Peter K. Chiang Cyclodextrin-peptide compositions
JPH08507442A (en) 1993-03-12 1996-08-13 セラテック，インコーポレイテッド Recombinant Epstein-Barr virus protein and use for vaccines
AU7935494A (en) 1993-10-25 1995-05-22 National Research Council Of Canada Bivalent thrombin inhibitors
US5840684A (en) * 1994-01-28 1998-11-24 Eli Lilly And Company Glycopeptide antibiotic derivatives
PE40996A1 (en) 1994-01-28 1996-10-14 Lilly Co Eli ANTIBIOTIC DERIVATIVE OF GLUCOPEPTIDE
SE510830C2 (en) * 1995-02-16 1999-06-28 Pure Pulse Technologies Inc Ways to pack fresh meat in a plastic packaging with good durability
US5919756A (en) 1996-06-28 1999-07-06 Eli Lilly And Company Amides
JP4215277B2 (en) * 1996-08-09 2009-01-28 アルコン ラボラトリーズ，インコーポレイテッド Preservative system for pharmaceutical compositions containing cyclodextrin
US5776912A (en) * 1996-12-20 1998-07-07 Schering Corporation Lipophilic oligosaccharide antibiotic compositions
US5916873A (en) * 1997-04-17 1999-06-29 Eli Lilly And Company Teicoplanin derivatives
US5874418A (en) * 1997-05-05 1999-02-23 Cydex, Inc. Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
US6046177A (en) * 1997-05-05 2000-04-04 Cydex, Inc. Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
ATE323110T1 (en) * 1997-07-01 2006-04-15 Pfizer Prod Inc METHOD FOR PRODUCING A CYCLODEXTRIN
GB2344713B (en) * 1998-02-10 2003-05-07 Furuno Electric Co Display system
EP1140999A1 (en) 1998-12-23 2001-10-10 Aventis Pasteur Limited $i(CHLAMYDIA) ANTIGENS AND CORRESPONDING DNA FRAGMENTS AND USES THEREOF
NZ508594A (en) 1998-12-23 2003-05-30 Theravance Inc Glycopeptide derivatives and pharmaceutical compositions containing the same
DE19911097A1 (en) * 1999-03-12 2000-09-14 Basf Ag Process for the preparation of solid dosage forms containing cyclodextrin
AU4054900A (en) 1999-04-02 2000-10-23 Advanced Medicine East, Inc. Desleucyl glycopeptide antibiotics and methods of making same
WO2001083520A2 (en) 2000-05-02 2001-11-08 Theravance,Inc Polyacid glycopeptide derivatives
WO2001082971A2 (en) 2000-05-02 2001-11-08 Theravance, Inc. Cyclodextrin containing glycopeptide antibiotic compositions
EP2263654B1 (en) 2000-06-21 2012-10-10 Cubist Pharmaceuticals, Inc. Compositions for improving the oral absorption of antimicrobial agents
US6872804B2 (en) 2000-06-22 2005-03-29 Theravance, Inc. Glycopeptide disulfide and thioester derivatives
WO2001098326A2 (en) * 2000-06-22 2001-12-27 Theravance, Inc. Glycopeptide disulfide and thioester derivatives
ES2302733T3 (en) 2000-06-22 2008-08-01 Theravance, Inc. CARBOXI-SACARIDS DERIVATIVES OF GLUCOPEPTIDE.
WO2001098329A1 (en) * 2000-06-22 2001-12-27 Theravance, Inc. Polyhydroxy glycopeptide derivatives
UA75083C2 (en) 2000-06-22 2006-03-15 Тераванс, Інк. Derivatives of glycopeptidephosphonates
US6969706B1 (en) * 2004-05-12 2005-11-29 Allergan, Inc. Preserved pharmaceutical compositions comprising cyclodextrins
WO2010004060A1 (en) * 2008-07-11 2010-01-14 Fundacion Para La Investigacion Biomedica Del Hospital Gregorio Marañon Use of cilastatin for reducing nephrotoxicity of different compounds

Also Published As

Publication number Publication date
JP4870314B2 (en) 2012-02-08
EP1278549A2 (en) 2003-01-29
ES2316445T3 (en) 2009-04-16
SI1278549T1 (en) 2009-04-30
US20060194717A1 (en) 2006-08-31
US6858584B2 (en) 2005-02-22
US20020077280A1 (en) 2002-06-20
CN1223378C (en) 2005-10-19
US20050026820A1 (en) 2005-02-03
US7067483B2 (en) 2006-06-27
US7026288B2 (en) 2006-04-11
CA2408008C (en) 2011-01-18
WO2001082971A3 (en) 2002-05-23
ATE416791T1 (en) 2008-12-15
US8158580B2 (en) 2012-04-17
EP1278549B1 (en) 2008-12-10
US7544364B2 (en) 2009-06-09
US20050032676A1 (en) 2005-02-10
WO2001082971A2 (en) 2001-11-08
AU2001259306A1 (en) 2001-11-12
CA2726789A1 (en) 2001-11-08
JP2008231109A (en) 2008-10-02
DE60136926D1 (en) 2009-01-22
US20100081609A1 (en) 2010-04-01
CN1441680A (en) 2003-09-10
JP2003531869A (en) 2003-10-28
BR0110530A (en) 2003-04-08

Similar Documents

Publication Publication Date Title
CA2408008A1 (en) Pharmaceutical compositions containing a glycopeptide antibiotic and a cyclodextrin
CA2411590A1 (en) Glycopeptide phosphonate derivatives
KR960700261A (en) 2, 6-Diaminopurine Derivatives,
HUP0001170A2 (en) Pharmaceutical compositions containing benzimidazole-2-carbamate derivatives as active ingredients for the treatment of viral infections and cancer
HUP9902121A2 (en) Indole derivatives as antagonists of gonadotropin releasing hormone and pharmaceutical compositions containing them
HUP0202367A2 (en) Fap-activated anti-tumor peptides, process for their preparation pharmaceutical compositions comprising thereof and their use
KR960704884A (en) Disamycin A analogues as antitumour or antiviral agents
CO5251429A1 (en) DERIVATIVES OF TER-BUTIL- (7-METHYL-IMIDAZO (1,2-A) PIRIDIN-3- IL) -AMINE PROCEDURE FOR PREPARATION, DRUGS THAT CONTAIN THEM, ITS USE FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE INHIBITION OF NON-SYNTHEASE AND PHARMACEUTICAL COMPOSITIONS THAT L
CZ289570B6 (en) Pharmaceutical formulation containing voriconazole
HUP9901296A2 (en) Substituted piperidine derivatives as nmda receptor antagonists and pharmaceutical compositions containing them
YU13695A (en) Application of 2-phenyl-3-aroylbenzothiophene and pharmaceutical formulations thereof
CA2290918A1 (en) Heteroaromatic bicyclic derivatives useful as anticancer agents
EP1070710A3 (en) Dithiolan derivatives, their preparation and their therapeutic effect
LU91178I2 (en) Emtricitabine / Tenofovir Disoproxil and its pharmaceutically acceptable derivatives (TRUVADA).
TR200103395T2 (en) 13-methyl erythromycin derivatives.
AP9801378A0 (en) 9-amino-3- keto erythromycin derivatives.
NZ308391A (en) Use of 1,2,4-triazole derivatives for the manufacture of a medicament for the treatment of cancers
RU2002100058A (en) 1-Methylcarbapenem Crystal Derivatives
CA2192555A1 (en) 2-acylaminopropanol compound and medicinal composition
RS50046B (en) PHARMACEUTICAL COMPOSITIONS OF TIZOXANIDE AND NITAZOXANIDE
EP0992509A3 (en) Novel macrolide derivatives
BR0015364A (en) Substituted 5-benzyl-2,4-diaminopyrimidines
CA2592436A1 (en) Antithrombotic dual inhibitors comprising a biotin residue
CA2373634A1 (en) Isophosphoramide mustard analogs and use thereof
EP0210753A3 (en) Anti-tumor medicament

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20210503